GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Debt-to-Equity

BCAX (Bicara Therapeutics) Debt-to-Equity : -0.00 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Debt-to-Equity?

Bicara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.30 Mil. Bicara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.22 Mil. Bicara Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-174.78 Mil. Bicara Therapeutics's debt to equity for the quarter that ended in Jun. 2024 was -0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bicara Therapeutics's Debt-to-Equity or its related term are showing as below:

BCAX's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Bicara Therapeutics Debt-to-Equity Historical Data

The historical data trend for Bicara Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Debt-to-Equity Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23
Debt-to-Equity
- -

Bicara Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Debt-to-Equity - N/A - -

Competitive Comparison of Bicara Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Bicara Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Debt-to-Equity falls into.


Bicara Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bicara Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.285 + 0.372) / -148.769
=-0.00

Bicara Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.3 + 0.217) / -174.776
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics  (NAS:BCAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bicara Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Debt-to-Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Website
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.